Verona Pharma plc - Company & Market Research Reports

Verona Pharma is a biopharmaceutical company that aims to improve the lives of those suffering from respiratory diseases by innovating therapeutic products. It was founded in 2005 in London, England. There proprietary lead candidate, RPL554 has opened a door to a whole new generation of drugs as it combines bronchodilator and an anti-inflammatory agent in a single compound. It has the potential to provide relief for the many patients suffering from respiratory conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and possibly asthma. Verona Pharma is listed on the NASDAQ global market and is supported by investors from U.S, U.K and Europe.

From
PDE Inhibitors Market, 2016-2026 - Product Thumbnail Image

PDE Inhibitors Market, 2016-2026

  • Report
  • 223 Pages
From
From
From
From
From
From
From
From
From
Asthma - Pipeline Review, H2 2018 - Product Thumbnail Image

Asthma - Pipeline Review, H2 2018

  • Drug Pipelines
  • 639 Pages
From
Asthma - Pipeline Review, H1 2018 - Product Thumbnail Image

Asthma - Pipeline Review, H1 2018

  • Drug Pipelines
  • 592 Pages
From
From
From
Cystic Fibrosis - Pipeline Review, H2 2018 - Product Thumbnail Image

Cystic Fibrosis - Pipeline Review, H2 2018

  • Drug Pipelines
  • 435 Pages
From
From
From
From
Cystic Fibrosis - Pipeline Review, H1 2018 - Product Thumbnail Image

Cystic Fibrosis - Pipeline Review, H1 2018

  • Drug Pipelines
  • 412 Pages
From
Loading Indicator
adroll